Patrick Page

Patrick oversees European partnerships, identifying and leading negotiation and licensing novel technologies or models, and being involved in corporate strategy and business planning. He has comprehensive knowledge of pharma, biotech, CRO/CDMO industry. Prior to joining Crown Bioscience, Patrick worked as project director at AstraZeneca and MerckSerono. He established, led or executed innovative small molecule or biological molecule projects and strategies in different therapeutic indications from target identification to PhII clinical trials. He designed 3 drugs Ebopiprant, Setanaxib and Nolasiban and has taken 12 more compounds across clinical development in oncology, respiratory, metabolic and cardiovascular diseases, fibrosis, and reproductive health. Patrick also co-founded and was CEO/CSO/COO of several biotech companies, Genkyotex in 2006 now acquired by Calliditas, Epire-med and Conicmeds, as well as two consultancy firms Huperion and Decode Pharma Partners. Patrick became Corporate Development Director at Crown Bioscience Inc. in 2021, working closely with multiple stakeholders internally and externally to support the Corporate Strategy and Development of the company. Patrick has authored 50+ publications and patents.